Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Prospective Phase III Clinical Trial of Neoadjuvant CapOx in Patients With Intermediate Risk CRM-negative Middle Rectal Cancer

NCT04134897 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT04134897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Prospective Phase III Clinical Trial of Neoadjuvant CapOx in Patients With Intermediate Risk CRM-negative Middle Rectal Cancer
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 3
Overall status
Unknown status
Start date
October 14, 2019
Completion date
October 31, 2024
Enrollment
316 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer, rectal neoplasms malignant, rectum carcinoma